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Selected abstracts and commentary
Archives of General Psychiatry 2006 Dec; 63:1386-1395.
CONTEXT: In animals, repeated exposure to stimulant drugs
leads to an enhanced drug-induced psychomotor response and
increased dopamine release. This phenomenon, known as
sensitization, may confer vulnerability to drug addiction or
drug-induced psychosis in humans. A similar phenomenon,
referred to as endogenous sensitization, is also believed to play
a role in the emergence of positive symptoms in patients with
schizophrenia. OBJECTIVE: To determine whether behavioral
and neurochemical sensitization occur in healthy individuals
after limited exposure to amphetamine in the laboratory.
DESIGN: Open-labe l, 1-year fol low-up of repeated
amphetamine administration in healthy volunteers. SETTING:
Department of Psychiatry, McGill University, and McConnell
Brain Imaging Center, Montreal Neurological Institute.
PARTICIPANTS: Ten healthy men (mean +/- SD age, 25.8 +/-
1.8 years) . INTERVENTION: Three sing le doses of
amphetamine (dextroamphetamine sulfate, 0.3 mg/kg by
mouth) were administered on days 1, 3, and 5. MAIN
OUTCOME MEASURES: Using positron emission tomography
and [11C]raclopride, we measured dopamine release in
response to amphetamine on the first exposure (day 1) and 14
days and 1 year after the third exposure. RESULTS: The initial
dose of amphetamine caused dopamine release in the ventral
striatum (a reduction in [11C]raclopride binding). Consistent
with a sensitization-like phenomenon, 14 and 365 days after
the third dose of  amphetamine there was a greater
psychomotor response and increased dopamine release (a
greater reduction in [11C]raclopride binding), relative to the
initial dose, in the ventral striatum, progressively extending to
the dorsal caudate and putamen. A high novelty-seeking
MODELING SENSITIZATION TO STIMULANTS IN HUMANS: AN [11C]RACLOPRIDE/POSITRON
EMISSION TOMOGRAPHY STUDY IN HEALTHY MEN
COMMENTARY
Is addiction an illness or simply bad behavior? Do addicts have a biological predisposition to become addicts or do they
only have themselves to blame? These questions have been debated by psychiatrists for most of the last century and have
had a major influence on how professionals approach treatment of drug addiction. Now Boileau et al show that on repeated
exposure to amphetamine the human brain becomes sensitized to it and releases relatively more dopamine on subsequent
administration of the substance with the effects lasting upto a year, suggesting that there may be a biological substrate to
addiction.
The discovery of atypical antipsychotics with decreased likelihood of causing extrapyramidal side effects at therapeutic
doses was heralded as a paradigm shift in the treatment of schizophrenia. But it soon became apparent that these drugs
had problems of their own with excessive weight gain, dyslipidemia, impaired glucose tolerance and type 2 diabetes
mellitus topping the list. Klein et al now show that concomitant use of metformin is safe and efficacious in abrogating
weight gain, decreased insulin sensitivity, and abnormal glucose metabolism in children and adolescents taking atypical
antipsychotics.
The tradition of diving illnesses into 'organic' and 'functional' has been a long one in psychiatry, somehow implying that
psychiatric illnesses were diseases of the 'mind' and not of the 'brain'. Many studies in the last quarter of a century have
shown that there were detectable abnormalities in the brain in patients with schizophrenia compared with normal controls.
Jayakumar et al add further weight to that evidence by demonstrating volumetric and metabolic abnormalities in caudate
nuclei of antipsychotic-naïve patients with schizophrenia compared with normal controls.
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personality trait and self-rating assessments indicating
impulsivi ty predicted proneness to sens it i zation.
CONCLUSIONS: Sensitization to stimulants can be achieved in
healthy men in the laboratory. This phenomenon is associated
with increased dopamine release and persists for at least 1
year.
OBJECTIVE: Second-generation, or atypical, antipsychotics
effectively treat psychiatric illness in children and adolescents.
However, weight gain and abnormalities in insulin sensitivity,
including diabetes, complicate this therapy. METHOD: A 16-
week double-blind, placebo-controlled trial was conducted to
evaluate the effectiveness of metformin in managing weight
gain in 39 subjects, ages 10-17, whose weight had increased
by more than 10% during less than 1 year of olanzapine,
risperidone, or quetiapine therapy. Body weight, body mass
index (kilograms per square meter of height), and waist
circumference were measured regularly, as were fasting insulin
and glucose levels. RESULTS: Weight was stabilized in subjects
receiving metformin, while those receiving placebo continued
to gain weight (0.31 kg/week). Because the study was
conducted with growing children, metformin treatment resulted
in reduction in z scores for both weight and body mass index.
The homeostasis model assessment, a surrogate indicator of
insulin sensitivity, decreased in treated subjects. Overt
diabetes was diagnosed in two subjects before treatment
(elevated baseline fasting glucose and insulin values) and in
two placebo-treated subjects (one at week 12 and the other
after study completion). One subject taking placebo developed
impaired fasting glucose. Placebo treatment was associated
with the need to perform oral glucose tolerance testing upon
study completion, by which three additional subjects were
identified with impaired glucose tolerance. No serious adverse
events resulted from metformin treatment. CONCLUSIONS:
Metformin therapy is safe and effective in abrogating weight
gain, decreased insulin sensitivity, and abnormal glucose
metabolism result ing from treatment o f ch ildren and
adolescents with atypicals.
Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA.
Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, USA. david.klein@cchmc.org.
American Journal of Psychiatry 2006 Dec; 163:2072-2079. 
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF METFORMIN
TREATMENT OF WEIGHT GAIN ASSOCIATED WITH INITIATION OF ATYPICAL ANTIPSYCHOTIC
THERAPY IN CHILDREN AND ADOLESCENTS
OBJECTIVE: To examine the volumetric and metabolic
correla tes of caudate nucleus in  antipsychotic-naive
schizophrenia patients in comparison with healthy controls.
METHOD: Twelve antipsychotic-naive schizophrenia patients
and 13 healthy controls underwent (31)P magnetic resonance
spectroscopy of basal ganglia. Magnetic resonance imaging
volume of caudate nuclei was measured using scion image
software. RESULTS: Patients had significantly smaller caudate
volume than healthy controls. Phosphocreatine (PCr)/total
phosphorous and PCr/total adenosine tri-phosphate ratios of
both caudate nuclei were significantly lower in patients than
controls. Significant negative correlation was found between
the left caudate volume and left PCr/total phosphorus ratio in
the patients. Age at onset of psychosis had i) significant
negative correlation with right and left caudate volumes and ii)
significant positive correlation with left PCr/total phosphorus
ratio. CONCLUSION: The metabolic and volumetric
abnormalities of caudate nucleus in antipsychotic-naive
schizophren ia patients  support neurodevelopmenta l
etiopathogenesis.
Jayakumar PN, Venkatasubramanian G, Keshavan MS, Srinivas JS, Gangadhar BN. 
Department of Neuroimaging and Interventional Radiology, National Institute of Mental Health and Neurosciences, Bangalore, India. jayakumar@nimhans.kar.nic.in
Acta Psychiatrica Scandinavica 2006 Nov; 114:346-351.
MRI VOLUMETRIC AND 31P MRS METABOLIC CORRELATES OF CAUDATE NUCLEUS IN
ANTIPSYCHOTIC-NAIVE SCHIZOPHRENIA
